170 related articles for article (PubMed ID: 34203607)
1. Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy.
Jurubiță R; Obrișcă B; Sorohan B; Achim C; Micu GE; Mircescu G; Ismail G
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34203607
[TBL] [Abstract][Full Text] [Related]
2. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
3. Anti-phospholipase A2 Receptor Antibody in Differentiation and Prognostication of Membranous Nephropathy.
Suthar KS; Vanikar AV; Patel RD; Kanodia KV; Nigam LA; Gandhi PA; Mehta AH
Saudi J Kidney Dis Transpl; 2022; 33(2):280-287. PubMed ID: 37417180
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
5. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.
Perna A; Ruggiero B; Podestà MA; Perico L; Orisio S; Debiec H; Remuzzi G; Ruggenenti P
Front Pharmacol; 2022; 13():958136. PubMed ID: 36120314
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis.
Li W; Zhao Y
Int Urol Nephrol; 2019 Sep; 51(9):1581-1596. PubMed ID: 31140029
[TBL] [Abstract][Full Text] [Related]
7. Serum 25-hydroxyvitamin D as a predictive biomarker of clinical outcomes in patients with primary membranous nephropathy.
Duan S; Chen S; Lu F; Zhou M; Jiang L; Chen C; Geng L; Sun R; Xu Y; Huang Z; Zhang C; Zhang B; Mao H; Xing C; Yuan Y
Front Nutr; 2023; 10():1171216. PubMed ID: 37181155
[TBL] [Abstract][Full Text] [Related]
8. PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy.
Ragy O; Bate S; Bukhari S; Hiremath M; Samani S; Khwaja A; Rao A; Kanigicherla DAK
Kidney Int Rep; 2023 Aug; 8(8):1605-1615. PubMed ID: 37547510
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults.
Wu X; Liu L; Guo Y; Yang L
Int J Nephrol Renovasc Dis; 2018; 11():241-247. PubMed ID: 30288080
[TBL] [Abstract][Full Text] [Related]
10. PLA2R antibody, PLA2R rs4664308 polymorphism and PLA2R mRNA levels in Tunisian patients with primary membranous nephritis.
Dhaouadi T; Abdellatif J; Trabelsi R; Gaied H; Chamkhi S; Sfar I; Goucha R; Ben Hamida F; Ben Abdallah T; Gorgi Y
PLoS One; 2020; 15(10):e0240025. PubMed ID: 33002091
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.
Netti GS; Infante B; Spadaccino F; Godeas G; Corallo MG; Prisciandaro C; Croce L; Rotondi M; Gesualdo L; Stallone G; Grandaliano G; Ranieri E
J Immunol Res; 2019; 2019():8483650. PubMed ID: 31781684
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function.
Ramachandran R; Prabakaran R; Priya G; Nayak S; Kumar P; Kumar A; Kumar V; Agrawal N; Rathi M; Kohli HS; Nada R
Nephron; 2022; 146(2):138-145. PubMed ID: 34818240
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous Nephropathy.
Kukuy OL; Cohen R; Gilburd B; Zeruya E; Weinstein T; Agur T; Dinour D; Beckerman P; Volkov A; Nissan J; Davidson T; Amital H; Shoenfeld Y; Shovman O
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240397
[TBL] [Abstract][Full Text] [Related]
14. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
Barrett C; Willcocks LC; Jones RB; Tarzi RM; Henderson RB; Cai G; Gisbert SI; Belson AS; Savage CO
Nephrol Dial Transplant; 2020 Apr; 35(4):599-606. PubMed ID: 31243451
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of M
Gong Z; Yuan S; Zhu X; Wang Y; Yu F; Yang D; Xu X; Liu H; Li J; Sun L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 45(6):693-700. PubMed ID: 32879127
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt HO; Tomas NM; Helmchen U; Panzer U; Stahl RA
Nephrol Dial Transplant; 2015 Nov; 30(11):1862-9. PubMed ID: 26142398
[TBL] [Abstract][Full Text] [Related]
18. [Membranous nephropathy in a Russian population].
Dobronravov VA; Mayer DA; Berezhnaya OV; Lapin SV; Mazing AV; Sipovsky VG; Smirnov AV
Ter Arkh; 2017; 89(6):21-29. PubMed ID: 28745685
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
20. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study.
Yin P; Wang J; Liang W; Zhan L; Liu Y; Lin J; Chen X; He Y; Jian H; Xie Z; Tan X; Ye Q; Huang F
Ren Fail; 2020 Nov; 42(1):675-683. PubMed ID: 32674643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
